1. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results;O'Shaughnessy;J Clin Oncol,2002
2. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer: the 303 Study Group;Chan;J Clin Oncol,1999
3. Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophophamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer (BC) patients: interim analysis of the BCIRG 001 study;Nabholtz;Proc ASCO,2002
4. Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: the European Organization for Research and Treatment of Cancer 10961 multicenter phase III trial;Biganzoli;J Clin Oncol,2002
5. Improved disease-free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (pts) with node-positive primary breast cancer (BC);Henderson;Proc ASCO,1998